MX2024007731A - Formulaciones del factor i del complemento. - Google Patents

Formulaciones del factor i del complemento.

Info

Publication number
MX2024007731A
MX2024007731A MX2024007731A MX2024007731A MX2024007731A MX 2024007731 A MX2024007731 A MX 2024007731A MX 2024007731 A MX2024007731 A MX 2024007731A MX 2024007731 A MX2024007731 A MX 2024007731A MX 2024007731 A MX2024007731 A MX 2024007731A
Authority
MX
Mexico
Prior art keywords
formulations
cfi
complement factor
wild
variants
Prior art date
Application number
MX2024007731A
Other languages
English (en)
Spanish (es)
Inventor
Bing Shan
Brian David Connolly
Sibu Balan
Anju Chatterji
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of MX2024007731A publication Critical patent/MX2024007731A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21045Complement factor I (3.4.21.45)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2024007731A 2021-12-22 2022-12-21 Formulaciones del factor i del complemento. MX2024007731A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163293013P 2021-12-22 2021-12-22
PCT/US2022/082179 WO2023122691A1 (en) 2021-12-22 2022-12-21 Complement factor-i formulations

Publications (1)

Publication Number Publication Date
MX2024007731A true MX2024007731A (es) 2024-07-01

Family

ID=85172701

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024007731A MX2024007731A (es) 2021-12-22 2022-12-21 Formulaciones del factor i del complemento.

Country Status (10)

Country Link
US (1) US20250009855A1 (enExample)
EP (1) EP4452321A1 (enExample)
JP (1) JP2025503483A (enExample)
KR (1) KR20240124950A (enExample)
CN (1) CN118450906A (enExample)
AU (1) AU2022420007A1 (enExample)
CA (1) CA3241714A1 (enExample)
IL (1) IL313777A (enExample)
MX (1) MX2024007731A (enExample)
WO (1) WO2023122691A1 (enExample)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201821082D0 (en) * 2018-12-21 2019-02-06 Gyroscope Therapeutics Ltd Combination of complement factors i and h, and vector encoding thereof
WO2021081348A1 (en) * 2019-10-23 2021-04-29 Gemini Therapeutics Inc. Methods for treating patients having cfi mutations with recombinant cfi proteins
CA3182800A1 (en) * 2020-06-14 2021-12-23 Vertex Pharmaceuticals Inc. Complement factor i-related compositions and methods

Also Published As

Publication number Publication date
AU2022420007A1 (en) 2024-06-20
WO2023122691A1 (en) 2023-06-29
EP4452321A1 (en) 2024-10-30
IL313777A (en) 2024-08-01
JP2025503483A (ja) 2025-02-04
US20250009855A1 (en) 2025-01-09
CN118450906A (zh) 2024-08-06
KR20240124950A (ko) 2024-08-19
CA3241714A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
Leong et al. Amoeboid and ramified microglia: their interrelationship and response to brain injury
CL2021001957A1 (es) Formulaciones que contienen proteína de fusión del receptor de vegf a alta concentración. (divisional solicitud 202002872)
CO2022002864A2 (es) Administración de vectores de virus adenoasociado de alfa-sarcoglicano y el tratamiento de la distrofia muscular
ES2109899T1 (es) Metodo, composiciones y kits para aumentar la biodisponibilidad oral de agentes farmaceuticos.
ES2083876T3 (es) Cateter para inyectar medicamentos.
ES2160485B1 (es) Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen.
ES2023095T3 (es) Cateter con zona en forma globular.
ES2092702T3 (es) Cateter con balon separable para tratamiento endoscopico.
DE602006016058D1 (de) Vorrichtungen zur Behandlung von empfänglicher Plaque
RU2002107319A (ru) Уменьшение объема ткани
Myung et al. Platelet‐rich plasma improves the therapeutic efficacy of mesenchymal stem cells by enhancing their secretion of angiogenic factors in a combined radiation and wound injury model
ES2182899T3 (es) Formulacion farmaceutica para la administracion subcutanea, intramuscular o intradermica de factor viii.
MX2021007241A (es) Acido ribonucleico (arn) que codifica para una proteina.
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
ES2093122T3 (es) Activacion mejorada de proteinas recombinantes.
MX2024007731A (es) Formulaciones del factor i del complemento.
ES2527664T3 (es) Tratamiento de la cistitis intersticial con una dosis alta de sulfato de condroitina
AR110031A1 (es) Métodos de tratamiento de pacientes con cáncer con inhibidores de farnesiltransferasa
AR128464A1 (es) Péptidos agonistas duales glp-1 y glucagón con estabilidad biológica mejorada
ES2119165T3 (es) Nueva actividad de cofactor anticoagulante.
CN105999527A (zh) 鼻腔给药装置
CN205107828U (zh) 肿瘤内科多功能介入治疗针
CN104288780A (zh) Gfp-30蛋白质和脂质体于制备治疗感音神经性耳聋或遗传性耳聋蛋白质药物中的应用
CN205494635U (zh) 一种新型用于体外膜肺氧合器官保护的双腔动脉灌注导管
ES1137507U (es) Dispositivo para inmovilización de tubos de administración de oxígeno en pacientes anestesiados.